Swissmedic Spotlights Personnel Roles: Essential Update for Teams
On November 28, 2025, Swissmedic released details regarding changes in personnel requirements within its Abteilung Personal und Organisation department. This…
Switzerland
Switzerland updates on medical device regulation and quality.
156 articles
156 articles in Switzerland
Europe
Europe
Swissmedic Announces HR Business Partner Opening: A Strategic Role in Regulatory Support
Swissmedic, the Swiss Agency for Therapeutic Products, has announced an exciting job opportunity for an HR Business Partner (60–80%). This…
Europe
Temporary Authorization for Ringerlactat B. Braun Infusion Solution in German Packaging
Swissmedic announces a temporary distribution authorization for Ringerlactat B. Braun Infusion Solution packaged in German labeling. As of November 27,…
Europe
Swissmedic Opens Access to Swissdamed UDI Devices Playground
Swissmedic has announced the release of the Swissdamed UDI Devices Playground, an online tool designed to assist medical device stakeholders…
Europe
Urgent Swissmedic Recall: Specific Batch of Azelastin-Fluticason-Mepha Nasal Spray Withdrawn
On November 27, 2025, Swissmedic announced an immediate recall of batch number 100062289 of Azelastin-Fluticason-Mepha Nasal Spray, Suspension. This recall…
Europe
Urgent Swissmedic Batch Recall: Lexotanil 3mg Tablets
On 26 November 2025, Swissmedic issued an official notice regarding the immediate recall of batch 1653102 of Lexotanil 3mg Tablets.…
Europe
Swissmedic Grants Initial Authorisation for Tepezza®: Key Implications for Regulatory Teams
Swissmedic announces the first authorisation of Tepezza®. This development is significant for quality, clinical, and regulatory professionals monitoring approvals of…
Europe
Swissmedic Authorizes Temporary Distribution of Glucose 5% Infusion Solution in German Packaging
Swissmedic has announced a temporary approval for the distribution of Glucose 5% B. Braun Infusionslösung in German packaging. This decision…
Europe
Swissmedic Approves Temporary Distribution of NaCl 0.9% Infusion in Foreign Packaging
On November 26, 2025, Swissmedic announced the temporary approval for distribution of NaCl 0.9% infusion solution from B. Braun in…
Europe
Swissmedic Announces Financial Consolidation Plan Amid Regulatory Priorities
Swissmedic, Switzerland’s key regulatory authority for therapeutic products, has outlined measures to strengthen its financial position. The announcement made 25…
Europe
Swissmedic Confirms First Authorisation for Lutathera®: Key Regulatory Update
On November 22, 2025, Swissmedic published an important regulatory update announcing the first authorisation of Lutathera®, a therapeutic option designed…
Europe
Swissmedic Expands Use of Breyanzi®: Updated Authorization Details
On November 22, 2025, Swissmedic announced the extension of the therapeutic indication for Breyanzi® (lisocabtagene maraleucel). This change has important…
Loading more articles…